Loading...
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
The development of CDK 4/6 inhibitors has dramatically changed the therapeutic management of hormone receptor-positive (HR+) and HER2 negative metastatic breast cancer (MBC). In combination with fulvestrant, palbociclib, ribociclib and abemaciclib have each been approved for HR+/HER2- MBC following...
Saved in:
| Published in: | Breast Cancer (Dove Med Press) |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7090187/ https://ncbi.nlm.nih.gov/pubmed/32256106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S196240 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|